A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy …

FA Shepherd, J Pereira, TE Ciuleanu… - Journal of Clinical …, 2004 - ascopubs.org
7022 Background: In phase II studies, erlotinib has shown single agent activity in a number
of tumor types, including NSCLC. NCIC CTG BR. 21 is a randomized, placebo-controlled …
被引用次数：415 相关文章

[引用][C] A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line …

FA Shepherd, J Pereira, TE Ciuleanu, EH Tan… - Journal of Clinical …, 2004 - cir.nii.ac.jp
A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell
lung cancer (NSCLC) following failure of 1< sup> st</sup> line or 2< sup> nd</sup> line …